Letybo (Botulinum Toxin Type A)

Letybo is a botulinum toxin type A product that acts on the neuromuscular junction to manage several disorders.

• Cervical dystonia: reduces abnormal neck muscle contractions and pain.
• Chronic migraine: decreases frequency of migraine days when injected in specific head muscles.
• Upper‑limb spasticity: improves range of motion by relaxing overactive forearm muscles.
• Hyperhidrosis: diminishes excessive sweating in the underarms.
• Glabellar lines (cosmetic): smooths frown lines by relaxing forehead muscles.

• Botulinum toxin type A cleaves SNAP‑25, a protein essential for vesicle fusion, thereby blocking the release of acetylcholine at the presynaptic nerve terminal. This inhibition prevents neuromuscular transmission, leading to temporary paralysis of the targeted skeletal muscle fibers until new nerve terminals are formed.

Adverse reactions are generally related to the injection site and the pharmacologic action of the toxin.

Common Side Effects

• Injection site pain: mild to moderate discomfort at the injection point.
• Bruising: localized discoloration due to minor bleeding.
• Headache: transient headache following treatment.
• Flu‑like symptoms: low‑grade fever or malaise.
• Localized muscle weakness: temporary reduction in strength of nearby muscles.
• Dry mouth: reduced salivation in the treated area.

Serious or Rare Side Effects

• Dysphagia: difficulty swallowing that may require medical attention.
• Respiratory compromise: weakness of respiratory muscles leading to breathing difficulty.
• Anaphylaxis: severe allergic reaction with rash, swelling, or airway obstruction.
• Spread of toxin effect: systemic weakness affecting distant muscles.
• Botulism‑like syndrome: generalized weakness, vision changes, or drooping eyelids.
• Severe infection: cellulitis or abscess at the injection site.

Prior to administration, clinicians should evaluate patient history and specific risk factors.

• Infection at injection site: avoid injecting into areas with active infection.
• Known hypersensitivity: do not use in patients with allergy to botulinum toxin or its excipients.
• Neuromuscular disorders: caution in patients with myasthenia gravis, Lambert‑Eaton syndrome, or ALS.
• Pregnancy and breastfeeding: safety not established; use only if potential benefit justifies risk.
• Elderly or debilitated patients: start with lower doses and monitor closely.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Botulinum toxin type A may interact with other agents that affect neuromuscular transmission.

Major Interactions (Avoid)

• Aminoglycoside antibiotics (e.g., gentamicin): can potentiate neuromuscular blockade.
• Quinolone antibiotics (e.g., ciprofloxacin): may increase risk of muscle weakness.
• Other neuromuscular blocking agents (e.g., curare, pancuronium): additive effect leading to severe paralysis.

Moderate Interactions (Monitor Closely)

• Calcium channel blockers (e.g., verapamil): may enhance toxin spread.
• Anticholinergic drugs (e.g., atropine): could modify clinical response.
• Concurrent botulinum toxin products: cumulative dosing may increase adverse events.